全文获取类型
收费全文 | 1074774篇 |
免费 | 71750篇 |
国内免费 | 1366篇 |
专业分类
耳鼻咽喉 | 15015篇 |
儿科学 | 34606篇 |
妇产科学 | 28623篇 |
基础医学 | 153389篇 |
口腔科学 | 29570篇 |
临床医学 | 94905篇 |
内科学 | 203624篇 |
皮肤病学 | 24391篇 |
神经病学 | 81439篇 |
特种医学 | 42961篇 |
外国民族医学 | 201篇 |
外科学 | 163089篇 |
综合类 | 21703篇 |
现状与发展 | 1篇 |
一般理论 | 263篇 |
预防医学 | 74599篇 |
眼科学 | 24554篇 |
药学 | 86102篇 |
7篇 | |
中国医学 | 2805篇 |
肿瘤学 | 66043篇 |
出版年
2019年 | 7757篇 |
2018年 | 11297篇 |
2017年 | 8906篇 |
2016年 | 10094篇 |
2015年 | 11262篇 |
2014年 | 15270篇 |
2013年 | 22199篇 |
2012年 | 30544篇 |
2011年 | 32290篇 |
2010年 | 18953篇 |
2009年 | 17813篇 |
2008年 | 29949篇 |
2007年 | 32067篇 |
2006年 | 32702篇 |
2005年 | 31027篇 |
2004年 | 29720篇 |
2003年 | 28549篇 |
2002年 | 27524篇 |
2001年 | 60019篇 |
2000年 | 61475篇 |
1999年 | 50927篇 |
1998年 | 12443篇 |
1997年 | 10999篇 |
1996年 | 11014篇 |
1995年 | 10320篇 |
1994年 | 9341篇 |
1993年 | 8857篇 |
1992年 | 37788篇 |
1991年 | 36273篇 |
1990年 | 35744篇 |
1989年 | 34285篇 |
1988年 | 30864篇 |
1987年 | 29986篇 |
1986年 | 28214篇 |
1985年 | 26448篇 |
1984年 | 19185篇 |
1983年 | 16113篇 |
1982年 | 8822篇 |
1979年 | 17029篇 |
1978年 | 11404篇 |
1977年 | 10229篇 |
1976年 | 8837篇 |
1975年 | 10068篇 |
1974年 | 11651篇 |
1973年 | 11273篇 |
1972年 | 10754篇 |
1971年 | 10092篇 |
1970年 | 9252篇 |
1969年 | 8939篇 |
1968年 | 7919篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
72.
B Nkgudi K A Robertson J Volmink B M Mayosi 《Suid-Afrikaanse tydskrif vir geneeskunde》2006,96(3):206-208
OBJECTIVE: To determine whether under-reporting of rheumatic fever occurs at hospital, municipal, provincial and national levels of the South African health system. BACKGROUND: Information on the incidence of rheumatic fever (RF) and the prevalence of rheumatic heart disease (RHD) is required for the prevention of valvular heart disease in developing countries. In South Africa, RF was made a notifiable condition in 1989. It has recently been suggested that the reporting of RF cases may be incomplete, possibly because of underreporting by health care professionals and deficient administration of the disease notification system in South Africa. METHOD AND RESULTS: We assessed whether underreporting of RF cases occurs by comparing the numbers of RF cases reported per year at hospital, municipal, provincial and national levels from 1990 to 2004. There was a fall in the number of RF cases reported per year at national and provincial level over the 15 years of observation. A detailed analysis of the number of RF cases reported at hospital, municipal and provincial level for a 5-year period showed that more cases were diagnosed in one hospital (serving a smaller population) than were captured at municipal and provincial level (serving a larger population), suggesting underreporting by health care professionals. There were discrepancies in the number of cases reported at municipal, provincial and national level, suggesting poor administration of the notification system. CONCLUSION: There appears to be underreporting of RF cases by health care professionals, and poor administration of the RF notification system. Health care professionals need to be educated about the statutory requirement to notify all RF cases in South Africa. An effective national disease notification system is required. 相似文献
73.
74.
75.
76.
Willemijn A K M Windt Atsua Tahara Alex C A Kluppel Dick de Zeeuw Robert H Henning Richard P E van Dokkum 《Journal of the renin-angiotensin-aldosterone system》2006,7(4):217-224
INTRODUCTION: Vasopressin, mainly through the V1a-receptor, is thought to be a major player in the maintenance of hyperfiltration. Its inhibition could therefore lead to a decrease in progression of chronic renal failure. To this end, the effect of the vasopressin V1a-receptor-selective antagonist, YM218, was studied on proteinuria and focal glomerulosclerosis in early and late intervention after 5/6 nephrectomy in rats, and compared with an angiotensin-converting enzyme inhibitor (ACE-I). MATERIALS AND METHODS: After 5/6 nephrectomy, early intervention was performed between week 2 and 10 thereafter with the V1a-receptor-selective antagonist (VRA, 10 mg/kg/day, n=10), enalapril (ACE-I, 10 mg/kg/day, n=9), or vehicle (n=8). Late intervention was performed in another group between week 6 and 12 with VRA (10 mg/kg/day, n=7), lisinopril (ACE-I, 5 mg/kg/day, n=7), or vehicle (n=7). RESULTS: In early intervention, proteinuria and focal glomerulosclerosis were significantly decreased by VRA compared to vehicle (44+7% and 59+8% respectively). ACE-I significantly decreased proteinuria (67+7%) and a trend towards a decrease in focal glomerulosclerosis was observed (30+18%). In late intervention, VRA did not decrease proteinuria and focal glomerulosclerosis compared to vehicle (21+20% and 0%, respectively), ACE-I significantly lowered proteinuria (92+2%) and a focal glomerulosclerosis (69+1%) lowering trend was observed. CONCLUSION: These results indicate that VRA may protect against early progression of renal injury after 5/6 nephrectomy, whereas its effectiveness seems limited in established renal damage. 相似文献
77.
78.
Both vascular surgery and endovascular interventions traumatise the arterial wall, especially the endothelium. The vessel responds with neointimal hyperplasia and/or constrictive remodelling, and this is still the limiting factor in curative interventions. Stent placement prevents constrictive remodelling but is the main trigger for in-stent restenosis. Hyperproliferation of neointimal tissue is the main response to arterial thrombosis, local inflammation or medio-intimal injury such as occurs, for example, after balloon dilatation in the region of arterial anastomoses or of a thrombectomy (Fogarty-manoeuvre). At present, research on prevention of restenosis is focused on inhibiting neointimal hyperproliferation by using drug-eluting stents, and especially sirolimus- or paclitaxel-eluting stents. In addition, further experimental research work is in progress, with the aim of esablishing new treatment regimens and solving the problem of neointimal formation, thrombosis and constrictive remodelling. These include both local and systemic pharmacological therapy, brachy- and laser therapy, and many genetic treatment options, some of which are currently the subjects of experimental studies and early-stage clinical trials. Gene therapy seems like a promising way of preventing restenosis, but has not yet been tested in clinical trials. In the near future, selective, simultaneous, and perhaps even polyphasic regulation for gene silencing of two or more genes involved in the development of restenosis could improve the long-term patency rate. 相似文献
79.
80.